Table 3 Characteristics of included randomized controlled trials
Study | Treatment duration | TAs | Control | Thrombotic events, n | History of thrombotic events as exclusion criteria, yes/no | |||
|---|---|---|---|---|---|---|---|---|
| Â | Â | Therapy | Patients, n | Method | Patients, n | TAs group | Control group | Â |
Bussel et al. 2007 | 6 weeks | Eltrombopag 30Â mg, 50Â mg, or 75Â mg | 88 | Placebo | 29 | 1: - Thromboembolism in the small vessels of the liver and kidneys | 0 | Yes: excluded patients with thrombosis within 1 year before enrolment or myocardial infarction within 3 months before enrolment |
Bussel et al. 2009 | 6 weeks | Eltrombopag 50 or 75Â mg | 76 | Placebo | 38 | 0 | 0 | Yes: excluded patients with thrombosis within the previous years |
Cheng et al. 2011 | 24 weeks | Eltrombopag 50Â mg, could be adjusted to 25Â mg or 75Â mg | 135 | Placebo | 62 | 3: 1 - Deep vein thrombosis 2 - Pulmonary embolism | 0 | Yes: excluded patients with arterial or venous thrombosis plus two or more thrombosis risk factors |
Huang et al. 2018 | 6 weeks | Eltrombopag 25Â mg, could be adjusted to 25Â mg or 75Â mg | 17 | Placebo | 18 | 1: - Cerebral infarction | 0 | Yes: excluded patients with history of arterial/venous thrombosis plus two or more thrombotic risk factors. |
Tomiyama et al. 2012 | 6 weeks | Eltrombopag 12.5–25 mg | 15 | Placebo | 8 | 1: - Transient ischemic attack | 0 | Yes: excluded patients with a history of arterial or venous thrombosis within 1 year before enrolment |
Yang et al. 2016 | 8 weeks | Eltrombopag 25–75 mg | 104 | Placebo | 51 | 2: - Cerebral infarction - Deep vein thrombosis | 0 | Yes: excluded patients with any prior history of cardiovascular disease |
Mei et al. 2021 | 10 weeks | Hetrombopag 2.5 or 5Â mg | 339 | Placebo | 85 | 1: - Acute myocardial infarction | 0 | Yes: excluded patients with venous or arterial thrombosis |
Bussel et al. 2014 | 4 weeks | Avatrombopag 2.5, 5, 10, 20Â mg | 59 | Placebo | 5 | 5: - Stroke - Myocardial infarction - Retinal artery occlusion - Iliac deep vein thrombosis - Superficial thrombophlebitis | 0 | Yes: excluded patients with history of cardiovascular disease, thromboembolic disease, deep vein thrombosis |
Jurczak et al. 2018 | 26 weeks | Avatrombopag 20Â mg, could be adjusted to 40Â mg or 5Â mg | 32 | Placebo | 17 | 3: - Deep vein thrombosis - Asymptomatic pulmonary embolism - Cerebrovascular event | 0 | Yes: excluded patients with clinically significant arterial or venous thrombosis and cardiovascular disease |
Bussel et al. 2006 | 6 weeks | Romiplostim 1, 3 or 6 µg/kg | 17 | Placebo | 4 | 0 | 1: - Popliteal deep vein thrombosis | Yes: any known risk factor for thromboembolic events or a history of cardiovascular disease |
Kuter et al. 2008 | 24 weeks | Romiplostim 1 or 2 µg/kg | 83 | Placebo | 42 | 2: - Popliteal artery thrombosis. - Stroke | 1: - Pulmonary embolism | No |
Kuter et al. 2010 | 52 weeks | Romiplostim 3–10 µg/kg | 157 | Standard of care | 77 | 11 (in 6 patients, include: 1 - Myocardial infarction 2 - Deep vein thrombosis 3 - Pulmonary embolism) | 2 (in 2 patients) | No |
Shirasugi et al. 2011 | 12 weeks | Romiplostim 3–10 µg/kg | 22 | Placebo | 12 | 0 | 0 | Yes: excluded patients with arterial thrombosis or a history of venous thrombosis necessitating anticoagulation therapy |
Gu et al. 2013 | 1 week | rhTPO 15000U, Methyllprednisolone 80Â mg | 31 | Methyllprednisolone 80Â mg | 31 | 1: - Acute myocardial infarction | 0 | Yes: excluded patients with history of thrombotic events |
Wang et al. 2012 | 4 weeks | rhTPO 1 µg/kg, Danazol 200 mg | 73 | Danazol 200 mg | 67 | 0 | 0 | Yes: excluded patients with history of thrombosis |
Yu et al. 2020 | 2 weeks | rhTPO 300 U/kg, Dexamethasone 40Â mg | 100 | Dexamethasone 40Â mg | 96 | 1: - Cerebral infarction | 0 | Yes: excluded patients with a history of arterial or venous thrombosis |
Zhou et al. 2015 | 2 weeks | rhTPO 300 U/kg, Rituximab 100Â mg | 77 | Rituximab 100Â mg | 38 | 1: - Myocardial infarction | 0 | No |